作者
Oliver Pfaar,Jay M. Portnoy,Hendrik Nolte,Adam Chaker,Jorge A. Luna‐Pech,Amber M. Patterson,Aarti Pandya,Désirée Larenas‐Linnemann
摘要
Allergen immunotherapy (AIT) is broadly used all over the world as the only available disease-modifying treatment option. The aim of this experts' perspective is to address 7 important unmet needs for the further direction of AIT and to provide the readership with the authors' positions on these topics. An international group of experts in the field of AIT have formulated 7 important aspects for the future position of AIT, performed a current literature review, and proposed a consented position on these topics. The aspects discussed and consented by the authors include: (1) alternative routes of allergen application in AIT, (2) potential of recombinant vaccines, (3) the role of allergy diagnosis based on component-resolved diagnosis for AIT composition, (4) the impact of COVID-19 vaccination for further innovations in AIT, (5) potential of combining biologics to AIT, (6) future innovations in high-risk children/adolescents, and (7) the future regulatory position on AIT. Important unmet needs and topics for AIT have been addressed in this expert review. The authors' views and personal position on these 7 aspects have also been elaborated. Allergen immunotherapy (AIT) is broadly used all over the world as the only available disease-modifying treatment option. The aim of this experts' perspective is to address 7 important unmet needs for the further direction of AIT and to provide the readership with the authors' positions on these topics. An international group of experts in the field of AIT have formulated 7 important aspects for the future position of AIT, performed a current literature review, and proposed a consented position on these topics. The aspects discussed and consented by the authors include: (1) alternative routes of allergen application in AIT, (2) potential of recombinant vaccines, (3) the role of allergy diagnosis based on component-resolved diagnosis for AIT composition, (4) the impact of COVID-19 vaccination for further innovations in AIT, (5) potential of combining biologics to AIT, (6) future innovations in high-risk children/adolescents, and (7) the future regulatory position on AIT. Important unmet needs and topics for AIT have been addressed in this expert review. The authors' views and personal position on these 7 aspects have also been elaborated. Immunotherapy in the ClinicThe Journal of Allergy and Clinical Immunology: In PracticeVol. 12Issue 1PreviewAllergen immunotherapy (AIT) is a clinically effective treatment for IgE-mediated allergic upper and lower airway diseases. More importantly, it confers long-term clinical benefit after discontinuation of treatment.1 As part of this month's themed issue, we take a look at the 6 most important topics in AIT. AIT's current status, dosing challenges in North America, application in allergic asthma, potential role in prevention of airway disease, understanding mechanisms and biomarkers in the clinic, and future prospects are appraised. Full-Text PDF